Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,018 recalls, newest first

Class II · Moderate risk

Chlorthalidone Tablets USP 25 mg

Foreign Matter identified as stainless steel microscopic wear particles mixed with punch lubricant oil and silicone particles from the dust cup

Terminated Particulate / foreign matter Sun Pharmaceutical Industries INC NDC 57664-648-88 D-0578-2022
Class II · Moderate risk

Prevantics

cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

Terminated cGMP deviation Professional Disposables International, Inc. NDC 10819-4077-1 D-0572-2022
Class II · Moderate risk

Prevantics

cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

Terminated cGMP deviation Professional Disposables International, Inc. NDC 10819-1080-1 D-0571-2022
Class II · Moderate risk

Prevantics

cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

Terminated cGMP deviation Professional Disposables International, Inc. NDC 10819-4076-4 D-0570-2022
Class I · High risk

MegMan Performance Booster

Marketed Without An Approved NDA/ANDA: product was found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Terminated Chemical / undeclared Junp Hydration LLC D-0557-2022
Class I · High risk

Morphine Sulfate PF 25 mg/25mL

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A

Terminated Labeling / mix-up STAQ Pharma, Inc. D-0634-2022
Class I · High risk

HYDROmorphone HCl PF 10 mg/50 mL

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A

Terminated Labeling / mix-up STAQ Pharma, Inc. D-0633-2022
Class I · High risk

Hard Dawn

Marketed Without an Approved NDA/ANDA: Firm was informed by Amazon that analytical testing showed the presence of tadalafil. Tadalafil is a FDA approved drug, making this product an unapproved drug.

Terminated Chemical / undeclared Esupplementsales, LLC D-0561-2022
Class II · Moderate risk

Cystex Tablet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. D-0555-2022
Class II · Moderate risk

Back Relief II

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-740-00 D-0551-2022
Class II · Moderate risk

Normed Fem Tablet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-701-00 D-0549-2022
Class II · Moderate risk

APAP 325 mg

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-700-00 D-0548-2022
Class II · Moderate risk

Migrenol Caplet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-565-00 D-0547-2022

Recalls by year